Physician profile
Sheba H Mohsin
NPI 1225290679
$1,117.61
in general payments reported to CMS, 2019-2025
17 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $65.17 · 2022: $132 · 2023: $144 · 2024: $75.29 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.40 | 2019-2023 | Tezspire |
| Amgen INC. | $178.96 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $106.27 | 2019-2025 | |
| Novo Nordisk INC | $102.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $87.02 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $59.07 | 2019 | |
| Merck Sharp & Dohme LLC | $46.82 | 2019-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $45.94 | 2019 | |
| Glaxosmithkline, LLC. | $41.07 | 2019-2023 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $39.71 | 2019-2020 | |
| Abbvie INC. | $36.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.94 | 2019-2024 | |
| Allergan, INC. | $29.46 | 2019-2020 | |
| Amarin Pharma, INC. | $19.87 | 2020 | |
| Currax Pharmaceuticals LLC | $17.47 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.28 | 2019 | |
| Mylan Specialty L.P. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheba Mohsin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.